On December 16, 2022, the U.S. Food and Drug Administration (FDA) granted a supplemental approval for Keytruda (pembrolizumab), specifically recognizing its efficacy. This approval, designated as BLA 125514 S-127 and sponsored by Merck Sharp Dohme, expands the therapeutic scope of this widely used immunotherapy.
Background
Pembrolizumab, known by its brand name Keytruda, is an established therapeutic agent. Supplemental approvals from the FDA typically indicate that new data has been submitted and reviewed, demonstrating the drug's efficacy for an additional use, patient population, or in a new treatment context. This specific approval falls under the 'Efficacy' class, meaning the FDA has evaluated and confirmed new evidence of the drug's effectiveness for an expanded application.
What this means
The supplemental FDA approval for Keytruda (pembrolizumab) on December 16, 2022, for efficacy, signifies an important expansion of its approved therapeutic applications. While the specific new indication, patient population, or treatment setting for this approval is not detailed in the provided information, such approvals are granted when new clinical data successfully demonstrates the drug's effectiveness in an additional context. This allows healthcare providers to consider Keytruda for a broader range of patients, based on the FDA's rigorous assessment of the new efficacy data submitted by the sponsor, Merck Sharp Dohme. This type of approval is crucial for extending the utility of established medications to benefit more patients.
Source
This information was obtained from the U.S. Food and Drug Administration (FDA) website. The approval details for Biologics License Application (BLA) 125514, specifically supplemental application S-127, were posted on December 16, 2022, on the accessdata.fda.gov domain. The event is categorized as a supplemental approval for efficacy, with Merck Sharp Dohme identified as the sponsor.